Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 505.87M P/E - EPS this Y 35.70% Ern Qtrly Grth -
Income -239.61M Forward P/E -1.99 EPS next Y -7.90% 50D Avg Chg -14.00%
Sales 161.42M PEG - EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -56.00%
Recommedations 2.80 Quick Ratio 0.21 Shares Outstanding 21M 52W Low Chg 14.00%
Insider Own 1.24% ROA -25.81% Shares Float 17.63M Beta 1.32
Inst Own 52.01% ROE - Shares Shorted/Prior 2.39M/2.24M Price 1.45
Gross Margin -37.72% Profit Margin -148.31% Avg. Volume 5,074,324 Target Price 16.50
Oper. Margin -117.42% Earnings Date Aug 8 Volume 3,487,658 Change -0.68%
About Agenus Inc.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFรŸ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Inc. News
07/26/24 The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
07/26/24 Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
07/19/24 Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
07/19/24 Lilly alone in bidding for Morphic; Novartis wonโ€™t yet file MorphoSys drug
07/18/24 Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
07/12/24 IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
06/28/24 Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
06/28/24 Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
06:30 AM Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
06/17/24 Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
06/13/24 Nature Medicine Reports Agenusโ€™ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
06/04/24 Agenus Announces Virtual Annual Shareholders Meeting
05/30/24 Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
11:32 AM 7 Biotech Stocks to Put on Your Breakthrough Radar
05/24/24 Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/23/24 Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
05/23/24 Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
05/22/24 3 Magnificent Growth Stocks to Buy Hand Over Fist
05/16/24 FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
05/08/24 Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
AGEN Chatroom

User Image MoneyTalksBullShitsWalks Posted - 6 hours ago

$AGEN cash flow is king, they will sell the company.

User Image BioRich Posted - 10 hours ago

$AGEN closing the week strong is nice for AH action and definitely big time movement next week. $BBIO $UPS $TERN $GUTS are expected to do well too. Like and Follow for more tips/suggestions. We'd love to hear yours too! Let's make some money! Cheers! #XaineSplaine

User Image BioRich Posted - 12 hours ago

@RamboTrader_ absolutely. Down 45% on a slight miss? We're taking that every time. Just entered. Wasn't even on my radar but couldn't pass this opportunity up. We've bought the over-exaggerated drops on $XFOR $AGEN $NRSN and $TNXP and have done quite well. Like and Follow for more tips/suggestions. We'd love to hear yours too! Let's make some money! Cheers!

User Image MarketDragon Posted - 12 hours ago

Stock Performance for $AGEN over the Last Month: Opening Price: $14.90 Closing Price: $5.97 Highest Price: $18.74 Lowest Price: $5.64 Percentage Change: -59.93% For more information: https://www.sahg6dtr.com/3K2CLMD/R74QP/

User Image dugger Posted - 14 hours ago

$AGEN Anyone have any inkling as to the whereabouts of dr. Kasi? I hope he continues his work on Bal-Bot.

User Image NakdEnergy Posted - 15 hours ago

@BioRich are you familiar with $AGEN? Any thoughts?

User Image GreenBendick Posted - 15 hours ago

News out $AGEN Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update https://marketwirenews.com/news-releases/agenus-to-provide-second-quarter-2024-financial-repo-6747956885660181.html $AGEN

User Image thegoldrushhurricane Posted - 17 hours ago

$AGEN

User Image OracleofOntario Posted - 18 hours ago

$AGEN just keep in mind that Ligand handed over $75M - hard to imagine they did so based solely on the expection that AGEN would get the AA. They couldn't have been that naive (or could they have been?)

User Image Stock_Titan Posted - 19 hours ago

$AGEN Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update https://www.stocktitan.net/news/AGEN/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-1x1y3pgii4zw.html

User Image neversurrender2024 Posted - 1 day ago

$AGEN below sounds like garo after he withdrew the bal bla ,he told his investors he saved the company $100 million.

User Image Stefman9 Posted - 1 day ago

$AGEN Garo is a Joke of a CEO and fast forwarded his son in the company, (with no medical experience leading a conference call is beyond belief). This company is just SAD with an amazing pipeline of drugs that will be slow walked to allowing other competitive drugs to overtake BOT. Plus Garo's reputation of getting nothing to market is definitely to be taken note of (30 years wasted). Garo's ego has shown his ability to make terrible decisions for shareholders but more importantly patients. I am a frustrated shareholder just waiting to hopefully recoup my money with a sale or collaboration. Hopefully now Garo's ego has been backed into a corner and he must make a large financial move, we will see. I am not confident. Luckily I have large gains in Tech stocks, and will wait to see if I use AGEN for tax purposes.

User Image 2_logs_higher Posted - 1 day ago

$AGEN

User Image AnalRetort Posted - 1 day ago

$AGEN Cheer up fellow bag holders. agen has a ridiculous amount of things going on, speaker presentation at esmo for bot/bal in sarcomas. The p2 can mature more and they can still get AA, AA isn't closed its on hold. IMO 2L+ MSS CRC NLM isn't worth that much anyway the approved drugs there are selling 200~400m. The move is to go for neoadjuvant Cornell is doing the 120 person study on that Nest-3. Data in pdac & lung is going to come out late 24 or early 25. Finally the grand daddy of them all is Harvard's Dr. Serzan who is working very hard at setting up a 120 person study ipi/nivo vs. bot/bal in renal cancer head to head. Rental cancer responds to ici, if bot/bal is truly differentiated [Which I still think the case] this study is going to show it. The study is powered to show a 10% benefit to bot/bal over ipi/nivo. Watch what happens to this stock if bot/bal is significantly superior to ipi/nivo. BOOM. Although it's a double edge sword, if its not better we are in deep shit.

User Image jlemx Posted - 1 day ago

$AGEN come on Garo, sell the whole thing, the more time passes the more Botensilimab and Agenus depreciate. You failed 2 times to bring IO in the market, third will not be allowed.

User Image MarcusEpi Posted - 1 day ago

$AGEN Nice fake pump and dump today stupid scam stock

User Image bombastic_ Posted - 1 day ago

$AGEN why are people still holding this smh

User Image Biotechguy21 Posted - 1 day ago

$AGEN the ๐Ÿคกshow continues. Buckle up fools

User Image docBNM Posted - 1 day ago

$AGEN doesn't seem to matter when this one gets short-sale restricted like today. The SEC is worthless... and brokers are greedy mfers

User Image thegoldrushhurricane Posted - 1 day ago

$AGEN

User Image ggoose18 Posted - 1 day ago

$AGEN https://www.medscape.com/viewarticle/865757 Garo and the โ€œexpertsโ€ couldnโ€™t do A simple google search to figure out they were going to get shot down?

User Image globallyhomeless Posted - 1 day ago

$AGEN back in at 5.94

User Image Moon37 Posted - 1 day ago

$AGEN at least we know penny is loaded so we will go up

User Image Biotechguy21 Posted - 1 day ago

$AGEN ๐Ÿ‘€๐Ÿ‘€๐Ÿ‘€ are you ready?

User Image neversurrender2024 Posted - 1 day ago

$AGEN garo should retire and go crush grapes for his sons wine company..... damage is done here.... turns out the man with a vision is blind as a bat....

User Image Biotechguy21 Posted - 1 day ago

$AGEN are you selling before this pos goes a lot lower? ๐Ÿ‘€๐Ÿ‘€๐Ÿคก๐Ÿคก๐Ÿ˜‚๐Ÿ˜‚

User Image Biotechguy21 Posted - 1 day ago

$AGEN say what? ๐Ÿ‘€๐Ÿ‘€๐Ÿ‘€๐Ÿ‘€

User Image Mlerro01 Posted - 1 day ago

$AGEN green light

User Image manny11419 Posted - 1 day ago

$AGEN I fully understand the feelings of the more rational posters here, I'm disappointed too. I'm down 90% with a basis around $4.24...but even in this cloudy times, one has to be rational, not emotional. I find myself going through all the PR and CC for the past two years..multiple times, maybe it offers solace...looking for anything positive to keep going. The company has significant value, worse case, it can be sold for over a billion, Bot/Bal rights to all indications, 120 acre land in vacaville, Mfg plant in emeryville, TiGit Bmy, Cd137, ILT4, hundred of patents. Lets not forget the valuable Nol's the cost of developing Bot/Bal...that an acquirer can use to offset profits.(worth tens of millions) I only invest in micro biotechs, for a reason...they rarely go bankrupt..they always merge with a larger partner

User Image neversurrender2024 Posted - 1 day ago

$AGEN couple hundred million, couple of years, hired a couple experts and they still got it wrong....

Analyst Ratings
Jefferies Hold Jul 19, 24
HC Wainwright & Co. Neutral Jul 18, 24
HC Wainwright & Co. Buy Jun 28, 24
HC Wainwright & Co. Buy May 24, 24
HC Wainwright & Co. Buy May 7, 24
B. Riley Securities Buy Mar 18, 24
HC Wainwright & Co. Buy Mar 14, 24
HC Wainwright & Co. Buy Aug 8, 23
EF Hutton Buy Jul 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
O'Day Steven J Chief Medical Office.. Chief Medical Officer Jan 04 Sell 3.06 38,679 118,358 61,321 01/06/22